Haw Par AI Stock Analysis
Want to see SG:H02 full AI Analyst Report?
Haw Par (H02) AI Stock Analysis
Haw Par
(SGX:H02)
The overall score of 73 reflects a company with exceptional financial strength and an attractive valuation, weighed down by a weak technical trend. The primary driver is the robust balance sheet and surging cash flows, which provide a strong margin of safety. The low P/E and solid dividend yield further support the case. However, the stock is in a clear downtrend, trading below all major moving averages, which presents a significant headwind and tempers the overall score.
Haw Par (H02) vs. iShares MSCI Singapore ETF (EWS)
- Market Cap
- SGD 2.18B
- Dividend Yield
- 3.24%
- Average Volume (3M)
- 267.84K
- Price to Earnings (P/E)
- 11.9
- Beta (1Y)
- 0.68
- Revenue Growth
- -13.24%
- EPS Growth
- -8.48%
- Country
- Singapore
- Employees
- 595
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Haw Par Business Overview & Revenue Model
Company Description
Established in Singapore in 1969, Haw Par Corporation Limited specializes in the manufacturing, marketing, and global trade of healthcare products, serving markets in Singapore, ASEAN countries, other Asian regions, and beyond. The company's business...
How the Company Makes Money
Haw Par makes money mainly through (1) consumer healthcare product sales and (2) income from its leisure/attractions activities, with additional contributions from (3) returns on its investment holdings. 1) Consumer healthcare (core operating revenue...
Haw Par Financial Statement Overview
Summary
Haw Par's financial health is excellent. The balance sheet is rock-solid with a 0.01 debt-to-equity ratio, and cash flow generation surged dramatically with a near 100% free cash flow conversion. Profitability is high, supported by a 56% gross margin, though the recent 9.1% revenue decline and reliance on investment income are minor concerns.
Income Statement
85Very PositiveBalance Sheet
90Very PositiveCash Flow
95Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 219.55M | 229.97M | 244.82M | 232.06M | 182.09M | 141.18M |
| Gross Profit | 121.94M | 128.76M | 134.09M | 134.89M | 98.57M | 73.64M |
| EBITDA | 73.32M | 73.45M | 250.11M | 233.49M | 49.06M | 119.45M |
| Net Income | 229.19M | 265.46M | 228.27M | 216.57M | 148.32M | 110.10M |
Balance Sheet | ||||||
| Total Assets | 4.88B | 4.42B | 4.28B | 3.59B | 3.65B | 3.28B |
| Cash, Cash Equivalents and Short-Term Investments | 881.34M | 834.71M | 3.93B | 3.21B | 3.18B | 596.23M |
| Total Debt | 52.60M | 44.27M | 36.30M | 28.48M | 58.40M | 1.52M |
| Total Liabilities | 133.88M | 126.83M | 128.47M | 117.17M | 101.41M | 72.08M |
| Stockholders Equity | 4.74B | 4.29B | 4.15B | 3.48B | 3.55B | 3.21B |
Cash Flow | ||||||
| Free Cash Flow | 224.94M | 269.17M | 50.33M | 54.92M | 21.21M | 14.46M |
| Operating Cash Flow | 227.34M | 271.29M | 53.79M | 62.68M | 40.94M | 18.84M |
| Investing Cash Flow | -187.29M | 76.93M | 199.82M | 258.00M | -261.58M | 87.52M |
| Financing Cash Flow | -70.80M | -300.68M | -82.79M | -79.30M | -38.07M | -65.11M |
Haw Par Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:H02, the sentiment is Negative. The current price of 12.36 is below the 20-day moving average (MA) of 12.77, below the 50-day MA of 13.02, and below the 200-day MA of 15.23, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 33.16 is Neutral, neither overbought nor oversold. The STOCH value of 10.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:H02.
Haw Par Peers Comparison
Overall Rating
SG:H0273Outperform
SG:BSL63Neutral
SG:A5048Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | SGD 2.74B | 11.88 | 5.07% | 3.24% | -13.24% | -8.48% | |
| 63Neutral | SGD 1.58B | 22.95 | 6.42% | 3.57% | -3.18% | 6.71% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | SGD 1.19B | -38.56 | -6.42% | ― | 6.44% | 38.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SG:H02 | Haw Par Corporation | 12.36 | -2.45 | -16.51% | |
| SG:BSL | Raffles Medical Group | 0.84 | -0.10 | -11.11% | |
| SG:A50 | Thomson Medical Group Ltd. | 0.04 | -0.01 | -22.41% | |
| SG:1J5 | Hyphens Pharma International Ltd. | 0.35 | 0.02 | 6.06% | |
| SG:40T | ISEC Healthcare Ltd | 0.31 | -0.02 | -5.78% | |
| SG:546 | Medtecs International Corporation Ltd. | 0.10 | -0.03 | -22.13% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
